«Now that we know exactly how changes in EMSY spur
cancer cell growth, we can start to design therapies to specifically target that activity and hopefully stop it,» says senior author Douglas Levine, MD, director of the Division of Gynecologic Oncology at NYU Langone and its Perlmutter Cancer C
cancer cell growth, we can start to design therapies to specifically target that activity and hopefully
stop it,» says senior author Douglas Levine, MD, director
of the Division
of Gynecologic Oncology
at NYU Langone and its Perlmutter
Cancer C
Cancer Center.